Undisclosed ARID1B degrader / Foghorn Therap - LARVOL DELTA

Foghorn is developing a Selective ARID1B degrader that is advancing towards in vivo proof of concept in 2026. Key program updates include: (Foghorn Press Release) - "Developed VHL and cereblon based bifunctional degraders with potential for oral delivery; Selective degradation of ARID1B achieved; Modulation of downstream target genes following ARID1B degradation"

Preclinical • Solid Tumor

Program Overview and Upcoming Milestones (GlobeNewswire) - "Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025...Selective CBP degrader program....On track for IND-enabling studies, targeting an IND in 2026."

IND • Preclinical • Diffuse Large B Cell Lymphoma • Estrogen Receptor Positive Breast Cancer • Hematological Malignancies • Multiple Myeloma • Solid Tumor

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update (GlobeNewswire) - "Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026; Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025."

IND • Preclinical • Oncology

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 (GlobeNewswire) - "Selective ARID1B degrader program: Developed highly potent and selective binders. Preclinical data demonstrated potent and selective small molecule binders to ARID1B; Selective degradation of ARID1B achieved. Foghorn has successfully selectively degraded ARID1B and expects to provide an update on the Selective ARID1B degrader program in 2025."

Preclinical • Bladder Cancer • Colorectal Cancer • Endometrial Cancer • Ovarian Cancer • Urothelial Cancer